PBM Disclosure Requirements For Rx Switches Likely To Increase Costs – FTC
This article was originally published in The Pink Sheet Daily
Executive Summary
Legislation pending in California would likely to discourage generic substitution, thereby increasing consumers’ costs, FTC says. Commission finds that the bill is more likely to undermine competition than promote it.
You may also be interested in...
California Bill On PBM Transparency Vetoed By Gov. Schwarzenegger
Measure “would have the unintended consequence of increasing drug costs” for insurers and Medi-Cal “without providing any real consumer benefit,” Schwarzenegger says. California becomes the tenth state to rebuff legislation that would impose certain disclosure requirements on PBMs, PCMA says.
California Bill On PBM Transparency Vetoed By Gov. Schwarzenegger
Measure “would have the unintended consequence of increasing drug costs” for insurers and Medi-Cal “without providing any real consumer benefit,” Schwarzenegger says. California becomes the tenth state to rebuff legislation that would impose certain disclosure requirements on PBMs, PCMA says.
PBM Transparency Requirements Needed To Protect Generic Switches – NCPA
A California bill mandating PBM disclosures related to drug substitution should be signed into law, the community pharmacists association says, disputing criticism of the proposal from the Federal Trade Commission. PCMA opposes the measure.